Bioelectronics Corp (BIEL)

[3331]

Revenue Projection = $10 Mil (PPS = .40)
But BIEL becomes the story stock for 2026 much sooner (PPS = .003). A move to .003 represents a 3,000% gain from .0001 — outperforming the 10-year ROI for Apple, Amazon, Netflix, Microsoft, Google, etc. We’re already 10% of the way there.

When this breakout hits, BIEL/Electrome will receive millions of dollars in free publicity, igniting global awareness and accelerating sales and big money will be chasing the stock

The BIEL Quantum Leap
BIEL is positioned to achieve in months what took Amazon, Netflix, Apple, Google, Tesla, and Nvidia decades to accomplish.

If BIEL delivers $2.5M in net profit and convinces investors of sustainable, disruptive growth, it could command a $2.5B market cap (PPS = $0.10).

That’s a 1000× P/E multiple, driven by narrative momentum — similar to Nvidia’s 100,000% rise from its all-time low.

P/E Ratios Above 1,000 Are NOT Unusual for High-Growth Disruptors
Examples of companies that traded at extreme P/E multiples during their explosive growth phases are:

Amazon — P/E > 1,000
Tesla — P/E > 1,100 (2021)
Salesforce — P/E > 1,200 (2020)
Zoom — P/E > 1,200 (2020)
Synaptics — P/E > 4,500 (2025)

High-growth, high-narrative companies routinely trade at P/E > 1,000 when investors believe:

The market is massive
The technology is disruptive
The growth curve is exponential
BIEL fits this profile perfectly if profitability aligns with the Electrome-driven narrative.

Profitability Is Within Reach
BIEL has already demonstrated how close it is:

Q3 2021 profit: $22,381
Revenue: $414,700 (includes $100K COVID relief)
Given BIEL’s ultra-lean operating model, sustained profitability is not theoretical — it’s imminent.

BIEL’s Fastest Path to Success
Hit $400K in quarterly revenue — enough for consistent profitability
Reach $1.5M in annual revenue — confirms sustainable growth
Leverage the new U.S. distributor — even a $300K valuation exits the trips; $1M pushes PPS to copper

Share Price Projection
Once profitability is achieved (or imminent), PPS is projected to hit copper ($0.01+).
Every additional $2.5M in annual profit adds roughly $0.01 (P/E = 100).

Valuation Scenarios (P/E =100 to 1000)
.001 Technical breakout (Golden Cross .0003, Blue-Sky .0006)
.003 3,000% gain when U.S. distributor news goes viral
.01 Profitability confirmed
.02 $5M profit (or $500k profit × 1000 P/E)
.04 $10M profit (or $1M profit × 1000 P/E)
.10 $25M profit (or $2.5M profit × 1000 P/E)
.40 $10M profit × 1000 P/E
$1.00 After debt payoff + stock buyback

Tax Advantage: A Hidden Accelerator
BIEL holds a $40M tax-loss carryforward, meaning the first $40M in profits are tax-free — accelerating net profitability.

BIEL’s Multi-Stream Royalty Revenue Model
BIEL is evolving into a pure-IP royalty engine with four monetizable product lines plus a clinical multiplier.

1️⃣ ActiPatch — Consumer Retail (Electrome-Driven)
Royalty: ~$2 per unit
Volume: 250K–1M
Annual revenue: $500K – $2M

2️⃣ RecoveryRx — Clinical / Post-Surgical (VLMS-Driven)
Royalty: $5–$7
Volume: 50K–200K
Annual revenue: $300K – $1.4M

3️⃣ RecoveryRx Veterinary — High-Margin Niche
Royalty: $5–$7.50
Volume: 20K–100K
Annual revenue: $100K – $750K

4️⃣ Vagus Nerve Stimulation Device — Patent Pending
Royalty: $10–$15
Volume: 50K–500K
Annual revenue: $500K – $5M

5️⃣ Phantom Limb Pain Study — Clinical Validation Multiplier
Adds +$300K annually
Accelerates global clinical uptake
Supports reimbursement

Combined Realistic Annual Revenue
ActiPatch: $800K
RecoveryRx: $600K
Veterinary: $240K
Vagus nerve: $1.2M
Phantom limb multiplier: $300K

Total realistic annual revenue: $3.1M – $4M
Best-case: $6M – $10M+

Stanford & Italian Thumb-Pain Studies Strengthen the Model
These studies are clinical force multipliers that increase the probability BIEL reaches the upper end of its revenue projections.

They strengthen:
RecoveryRx’s clinical credibility
Insurance reimbursement pathways
VA/DoD adoption
Hospital acceptance
Neuromodulation validation (supports vagus nerve device)
Electrome’s DARPA-aligned roadmap

They demonstrate:
Non-pharmaceutical pain reduction
Inflammation modulation
Neuromodulation efficacy
Faster soft-tissue recovery

The thumb studies don’t change the revenue numbers, but they reinforce the same pillars as the phantom-limb-pain study — credibility, reimbursement, and adoption.

Why This Model Finally Works
Viant (Sree Koneru):
Scalable FDA-grade manufacturing
Lower cost of goods
Ability to fulfill large retail orders

VLMS (Keith Nalepka):
Opens global clinical channels
Drives hospital adoption
Adds veterinary markets

Electrome:
Drives consumer rollout
Invests in branding & packaging

BIEL:
Provides patents, technology, and IP backbone

For the first time, BIEL has the ecosystem to become a multi-stream royalty company instead of a single-product OTC struggler.

Electrome’s JPM + DARPA Momentum: A Major Validation Signal
Electrome’s CMO, Dr. Nevena Zubcevik, reported strong investor engagement at JPM 2026 and alignment with DARPA-related national-security innovation. This confirms Electrome is:
Funded
Credible
Ambitious
Strategically aligned with BIEL’s IP
This increases the probability that the upper end of BIEL’s revenue model becomes achievable.

The Stanford & Italian thumb-pain studies now join:
Phantom-limb-pain validation
Electrome’s DARPA alignment
VLMS’s clinical expansion
Viant’s manufacturing scale

Together, they strengthen the case that BIEL’s multi-stream royalty model is not only realistic — it’s accelerating.